Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTCH1 | P46531 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7237628 | 0.81 | ALDH1A1 (0.46) | NOTCH1ALDH1A1HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL9505147 | 0.77 | ADRA2A (0.51) | NOTCH1ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL7253466 | 0.77 | KDM4E (0.38) | NOTCH1ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL7239201 | 0.74 | CACNA1B (0.53) | NOTCH1ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL7240134 | 0.72 | ADRA1A (0.51) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL4254046 | 0.70 | ALDH1A1 (0.63) | ALDH1A1HPGDHSD17B10TSHRKDM4E | |
| SCHEMBL9345653 | 0.66 | HDAC4 (0.50) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL10617897 | 0.65 | ADRA2A (0.59) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL25541795 | 0.64 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL9350057 | 0.62 | ADRA2A (0.38) | ADRA2AADRA2BADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608086-B2 | Selective adrenergic receptor alpha 1C antagonists without significant calcium channel activity; treating benign prostatic hyperplasia, intraocular pressure and inhibiting cholesterol synthesis | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-08-19 | — | — | US | disclosed |
| US-20020193599-A1 | Dihydropyridines and new uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-12-19 | — | — | US | disclosed |
| US-6310076-B1 | TREATING BENIGN PROSTATIC HYPERPLASIA, LOWERING INTRAOCULAR PRESSURE, INHIBITING CHOLESTEROL SYNTHESIS, TREATING DISEASES MEDIATED BY ALPHA-1 RECEPTORS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-10-30 | — | — | US | disclosed |
| US-6211198-B1 | BENIGN PROSTATE HYPERPLASIA; INTRAOCULAR PRESSURE; HYPOTENSIVE AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-04-03 | — | — | US | disclosed |
| US-5767131-A | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA, INHIBITION OF CHOLESTEROL SYNTHESIS, LOWERING OF INTRAOCULAR PRESSURE; ALPHA-ADRENERGIC RECEPTOR DISEASES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-06-16 | — | — | US | disclosed |
| WO-1994022829-A2 | DIHYDROPYRIDINES AND NEW USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193599-A1 | Dihydropyridines and new uses thereof | BPHL, BCKDK, DHCR7 | NOTCH1 4000/4885ADRA2A 84/4885ADRA2B 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.